Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · JUBLPHARMA

JUBLPHARMA

HealthcarePharmaceuticals & Biotechnology₹14796 cr market cap
₹933.25 ▼ -0.04% today As of 19 Nov 2026
52-week low ₹807.6552-week high ₹1158.90

-19.4% from the 52-week high · +15.6% above the low

Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. The company is headquartered in Noida, Uttar Pradesh and currently employs 1,034 full-time employees. The firm's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

The short version. JUBLPHARMA reported revenue of ₹2,370 crore for Sep 2026, up 20.5% from a year earlier. Net profit was ₹31 crore (down 74.2% year on year). Return on equity was 5.6% in Mar 2026. Promoter holding was 47.68% in Sep 2026, down 3.00 points over 8 quarters.

1 · The price

How has the stock traded?

JUBLPHARMA trades 19.4% below its 52-week high and 15.6% above its 52-week low.

Change over period: —

1M-0.2%
3M+7.6%
6M-7.9%
1Y-17.8%

2 · The business

Is it growing?

Sales, year on year+20.5%

Sep 2026 revenue of ₹2,370 cr.

Profit, year on year-74.2%

Sep 2026 net profit of ₹31 cr.

Net margin1.3%

4.8 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue23702229229021221966190119291822
Net profit315611956120103154101
Net margin %1.32.55.22.66.15.48.05.5
EPS (₹)1.963.557.53.517.556.469.646.33

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue82807234670362826059609991549111
Net profit39883977-61414836898574
Net margin %4.811.61.2-1.06.813.79.86.3
EPS (₹)25.0252.74.84-3.8325.9952.4856.3936.07

3 · The quality

How well does it turn capital into profit?

Return on equity was 5.6% in Mar 2026; debt to equity is 0.45.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %5.613.414.2-1.1
Return on capital %6.411.543.42.2
EBITDA margin %15.221.811.812.0
Net margin %4.811.51.1-1.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.7%6.4%
Profit CAGR—-13.8%
Debt to equity0.45
Interest cover3.9x
Current ratio1.62
P/E ratio35.7

4 · The owners

Who holds it, and are they adding?

Promoter holding47.68%

Down 3.0 pts over 8 quarters.

Foreign institutions15.38%

Down 1.58 pts over 8 quarters.

Domestic institutions13.02%

Up 6.04 pts over 8 quarters.

Mutual fund schemes34

+7 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter50.6850.6847.6847.6847.6847.6847.6847.68-3.0
FII16.9617.2217.416.5715.9615.915.8715.38-1.58
DII6.987.059.5310.5211.2211.6212.413.02+6.04
Public24.8324.524.8424.624.5724.2423.523.38-1.45

Mutual fund holdings · Oct 2026

34 schemes hold this stock

27 the month before.

  • Bandhan Focused Fund5.92% of NAV
  • Kotak Consumption Fund1.61% of NAV
  • Bandhan Small Cap Fund1.56% of NAV
  • Kotak Special Opportunities Fund1.46% of NAV
  • THE WEALTH COMPANY MULTI CAP FUND1.3% of NAV
  • Abakkus Small Cap Fund1.29% of NAV
  • Abakkus Large & Mid Cap Fund1.28% of NAV
  • Kotak Healthcare Fund1.08% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for JUBLPHARMA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about JUBLPHARMA

What is the JUBLPHARMA share price?

JUBLPHARMA (JUBLPHARMA) last closed at ₹933.25, down 0.04% on the day. Its 52-week range is ₹807.65 to ₹1,158.90.

What is the market cap of JUBLPHARMA?

JUBLPHARMA has a market capitalisation of about ₹14,796 crore. Its price-to-earnings ratio is 35.7.

How are JUBLPHARMA's latest results?

JUBLPHARMA reported revenue of ₹2,370 crore for Sep 2026, up 20.5% from a year earlier. Net profit was ₹31 crore (down 74.2% year on year). Return on equity was 5.6% in Mar 2026. Promoter holding was 47.68% in Sep 2026, down 3.00 points over 8 quarters.

Who owns JUBLPHARMA?

As of Sep 2026, shareholding was: Promoter 47.68%, FII 15.38%, DII 13.02%, Public 23.38%.

How many mutual funds hold JUBLPHARMA?

34 mutual fund schemes held JUBLPHARMA in October 2026. That compares with 27 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 25 Jul 2025 · Final Dividend - Rs. 5
  • 02 Aug 2024 · Final Dividend - Rs. 5
  • 10 Aug 2023 · Final Dividend - Rs. 5
  • 11 Aug 2022 · Final Dividend - Rs. 5
  • 05 Aug 2021 · Final Dividend - Rs. 5
  • 09 Mar 2020 · Interim Dividend - Rs. 5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.